Spinally administered dynorphin A produces long-lasting allodynia

Involvement of NMDA but not opioid receptors

T. M. Laughlin, Todd W Vanderah, J. Lashbrook, M. L. Nichols, M. Ossipov, Frank Porreca, G. L. Wilcox

Research output: Contribution to journalArticle

165 Citations (Scopus)

Abstract

The endogenous opioid peptide dynorphin A has non-opioid effects that can damage the spinal cord when given in high doses. Dynorphin has been shown to increase the receptive field size of spinal cord neurons and facilitate C- fiber-evoked reflexes. Furthermore, endogenous dynorphin levels increase following damage to the spinal cord, injury to peripheral nerves, or inflammation. In this study, sensory processing was characterized following a single, intrathecal injection of dynorphin A (1-17) in mice. A single intrathecal injection of dynorphin A (1-17) (3 nmol, i.t.) induced mechanical allodynia (hind paw, von Frey filaments) lasting 70 days, tactile allodynia (paint brush applied to flank) lasting 14 days, and cold allodynia (acetone applied to the dorsal hind paw) lasting 7 days. Similarly, dynorphin A (2- 17) (3 nmol, i.t.), a non-opioid peptide, induced cold and tactile allodynia analogous to that induced by dynorphin A (1-17), indicating the importance of non-opioid receptors. Pretreatment with the NMDA antagonists, MK-801 and LY235959, but not the opioid antagonist, naloxone, blocked the induction of allodynia. Post-treatment with MK-801 only transiently blocked the dynorphin- induced allodynia, suggesting the NMDA receptors may be involved in the maintenance of allodynia as well as its induction. We have induced a long- lasting state of allodynia and hyperalgesia by a single intrathecal injection of dynorphin A (1-17) in mice. The allodynia induced by dynorphin required NMDA receptors rather than opioid receptors. This result is consistent with results in rats and with signs of clinically observed neuropathic pain. This effect of exogenously administered dynorphin raises the possibility that increased levels of endogenous dynorphins associated with spinal cord injuries may participate in the genesis and maintenance of neuropathic pain.

Original languageEnglish (US)
Pages (from-to)253-260
Number of pages8
JournalPain
Volume72
Issue number1-2
DOIs
StatePublished - 1997
Externally publishedYes

Fingerprint

Dynorphins
Hyperalgesia
Opioid Receptors
N-Methylaspartate
Spinal Injections
Dizocilpine Maleate
Neuralgia
N-Methyl-D-Aspartate Receptors
Spinal Cord Injuries
LY 235959
Spinal Cord
Maintenance
Unmyelinated Nerve Fibers
Paint
Opioid Peptides
Narcotic Antagonists
Naloxone
Acetone
Peripheral Nerves
Reflex

Keywords

  • Allodynia
  • Dynorphin A
  • NMDA
  • Spinal cord

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Neurology
  • Neuroscience(all)
  • Pharmacology
  • Clinical Psychology

Cite this

Spinally administered dynorphin A produces long-lasting allodynia : Involvement of NMDA but not opioid receptors. / Laughlin, T. M.; Vanderah, Todd W; Lashbrook, J.; Nichols, M. L.; Ossipov, M.; Porreca, Frank; Wilcox, G. L.

In: Pain, Vol. 72, No. 1-2, 1997, p. 253-260.

Research output: Contribution to journalArticle

Laughlin, T. M. ; Vanderah, Todd W ; Lashbrook, J. ; Nichols, M. L. ; Ossipov, M. ; Porreca, Frank ; Wilcox, G. L. / Spinally administered dynorphin A produces long-lasting allodynia : Involvement of NMDA but not opioid receptors. In: Pain. 1997 ; Vol. 72, No. 1-2. pp. 253-260.
@article{b90865598bf54c178332475b227d6712,
title = "Spinally administered dynorphin A produces long-lasting allodynia: Involvement of NMDA but not opioid receptors",
abstract = "The endogenous opioid peptide dynorphin A has non-opioid effects that can damage the spinal cord when given in high doses. Dynorphin has been shown to increase the receptive field size of spinal cord neurons and facilitate C- fiber-evoked reflexes. Furthermore, endogenous dynorphin levels increase following damage to the spinal cord, injury to peripheral nerves, or inflammation. In this study, sensory processing was characterized following a single, intrathecal injection of dynorphin A (1-17) in mice. A single intrathecal injection of dynorphin A (1-17) (3 nmol, i.t.) induced mechanical allodynia (hind paw, von Frey filaments) lasting 70 days, tactile allodynia (paint brush applied to flank) lasting 14 days, and cold allodynia (acetone applied to the dorsal hind paw) lasting 7 days. Similarly, dynorphin A (2- 17) (3 nmol, i.t.), a non-opioid peptide, induced cold and tactile allodynia analogous to that induced by dynorphin A (1-17), indicating the importance of non-opioid receptors. Pretreatment with the NMDA antagonists, MK-801 and LY235959, but not the opioid antagonist, naloxone, blocked the induction of allodynia. Post-treatment with MK-801 only transiently blocked the dynorphin- induced allodynia, suggesting the NMDA receptors may be involved in the maintenance of allodynia as well as its induction. We have induced a long- lasting state of allodynia and hyperalgesia by a single intrathecal injection of dynorphin A (1-17) in mice. The allodynia induced by dynorphin required NMDA receptors rather than opioid receptors. This result is consistent with results in rats and with signs of clinically observed neuropathic pain. This effect of exogenously administered dynorphin raises the possibility that increased levels of endogenous dynorphins associated with spinal cord injuries may participate in the genesis and maintenance of neuropathic pain.",
keywords = "Allodynia, Dynorphin A, NMDA, Spinal cord",
author = "Laughlin, {T. M.} and Vanderah, {Todd W} and J. Lashbrook and Nichols, {M. L.} and M. Ossipov and Frank Porreca and Wilcox, {G. L.}",
year = "1997",
doi = "10.1016/S0304-3959(97)00046-8",
language = "English (US)",
volume = "72",
pages = "253--260",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Spinally administered dynorphin A produces long-lasting allodynia

T2 - Involvement of NMDA but not opioid receptors

AU - Laughlin, T. M.

AU - Vanderah, Todd W

AU - Lashbrook, J.

AU - Nichols, M. L.

AU - Ossipov, M.

AU - Porreca, Frank

AU - Wilcox, G. L.

PY - 1997

Y1 - 1997

N2 - The endogenous opioid peptide dynorphin A has non-opioid effects that can damage the spinal cord when given in high doses. Dynorphin has been shown to increase the receptive field size of spinal cord neurons and facilitate C- fiber-evoked reflexes. Furthermore, endogenous dynorphin levels increase following damage to the spinal cord, injury to peripheral nerves, or inflammation. In this study, sensory processing was characterized following a single, intrathecal injection of dynorphin A (1-17) in mice. A single intrathecal injection of dynorphin A (1-17) (3 nmol, i.t.) induced mechanical allodynia (hind paw, von Frey filaments) lasting 70 days, tactile allodynia (paint brush applied to flank) lasting 14 days, and cold allodynia (acetone applied to the dorsal hind paw) lasting 7 days. Similarly, dynorphin A (2- 17) (3 nmol, i.t.), a non-opioid peptide, induced cold and tactile allodynia analogous to that induced by dynorphin A (1-17), indicating the importance of non-opioid receptors. Pretreatment with the NMDA antagonists, MK-801 and LY235959, but not the opioid antagonist, naloxone, blocked the induction of allodynia. Post-treatment with MK-801 only transiently blocked the dynorphin- induced allodynia, suggesting the NMDA receptors may be involved in the maintenance of allodynia as well as its induction. We have induced a long- lasting state of allodynia and hyperalgesia by a single intrathecal injection of dynorphin A (1-17) in mice. The allodynia induced by dynorphin required NMDA receptors rather than opioid receptors. This result is consistent with results in rats and with signs of clinically observed neuropathic pain. This effect of exogenously administered dynorphin raises the possibility that increased levels of endogenous dynorphins associated with spinal cord injuries may participate in the genesis and maintenance of neuropathic pain.

AB - The endogenous opioid peptide dynorphin A has non-opioid effects that can damage the spinal cord when given in high doses. Dynorphin has been shown to increase the receptive field size of spinal cord neurons and facilitate C- fiber-evoked reflexes. Furthermore, endogenous dynorphin levels increase following damage to the spinal cord, injury to peripheral nerves, or inflammation. In this study, sensory processing was characterized following a single, intrathecal injection of dynorphin A (1-17) in mice. A single intrathecal injection of dynorphin A (1-17) (3 nmol, i.t.) induced mechanical allodynia (hind paw, von Frey filaments) lasting 70 days, tactile allodynia (paint brush applied to flank) lasting 14 days, and cold allodynia (acetone applied to the dorsal hind paw) lasting 7 days. Similarly, dynorphin A (2- 17) (3 nmol, i.t.), a non-opioid peptide, induced cold and tactile allodynia analogous to that induced by dynorphin A (1-17), indicating the importance of non-opioid receptors. Pretreatment with the NMDA antagonists, MK-801 and LY235959, but not the opioid antagonist, naloxone, blocked the induction of allodynia. Post-treatment with MK-801 only transiently blocked the dynorphin- induced allodynia, suggesting the NMDA receptors may be involved in the maintenance of allodynia as well as its induction. We have induced a long- lasting state of allodynia and hyperalgesia by a single intrathecal injection of dynorphin A (1-17) in mice. The allodynia induced by dynorphin required NMDA receptors rather than opioid receptors. This result is consistent with results in rats and with signs of clinically observed neuropathic pain. This effect of exogenously administered dynorphin raises the possibility that increased levels of endogenous dynorphins associated with spinal cord injuries may participate in the genesis and maintenance of neuropathic pain.

KW - Allodynia

KW - Dynorphin A

KW - NMDA

KW - Spinal cord

UR - http://www.scopus.com/inward/record.url?scp=0030879183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030879183&partnerID=8YFLogxK

U2 - 10.1016/S0304-3959(97)00046-8

DO - 10.1016/S0304-3959(97)00046-8

M3 - Article

VL - 72

SP - 253

EP - 260

JO - Pain

JF - Pain

SN - 0304-3959

IS - 1-2

ER -